Introduction: Alzheimer's disease (AD) is a major global public health challenge. To date, no treatments have been shown to stop the underlying pathological processes. The cerebral accumulation of amyloid-beta (Ab) is still considered as the primum movens of AD and disease-modifying treatments targeting Ab are reaching - or have already reached - clinical practice. Areas covered: The authors explore the main advancements from Aβ-targeting monoclonal antibodies (mAbs) for the treatment of AD. From a public health perspective, they address ethically relevant issues such as the benevolence and non-maleficence principles. They report on the potential biological and clinical benefits of these drugs, discussing minimal clinically important differences (MCID) and other relevant outcomes. They examine the short- and long-term effects of amyloid-related imaging abnormalities (ARIA), and explore the differences between eligibility criteria in clinical trials, appropriate use recommendations, and prescribing information content. In doing so, they contextualize the discussion on the disagreements among different regulatory authorities. Expert opinion: Although anti-β-amyloid monoclonal antibodies may be effective in selected scenarios, non-negligible knowledge gaps and implementation limits persist. Overcoming these gaps can no longer be postponed if we are to ensure the principles of Quality of Care for patients with cognitive impairment who would be eligible for this class of drugs.
Advances in amyloid-targeting monoclonal antibodies for Alzheimer's disease: clinical and public health issues / Salemme, Simone; Ancidoni, Antonio; Locuratolo, Nicoletta; Piscopo, Paola; Lacorte, Eleonora; Canevelli, Marco; Vanacore, Nicola. - In: EXPERT REVIEW NEUROTHERAPEUTICS. - ISSN 1744-8360. - (2023), pp. 1-17. [10.1080/14737175.2023.2284305]
Advances in amyloid-targeting monoclonal antibodies for Alzheimer's disease: clinical and public health issues
Salemme, SimonePrimo
Writing – Original Draft Preparation
;Ancidoni, AntonioSecondo
Writing – Original Draft Preparation
;Locuratolo, NicolettaWriting – Review & Editing
;Piscopo, PaolaWriting – Review & Editing
;Canevelli, MarcoPenultimo
Writing – Review & Editing
;Vanacore, Nicola
Ultimo
Supervision
2023
Abstract
Introduction: Alzheimer's disease (AD) is a major global public health challenge. To date, no treatments have been shown to stop the underlying pathological processes. The cerebral accumulation of amyloid-beta (Ab) is still considered as the primum movens of AD and disease-modifying treatments targeting Ab are reaching - or have already reached - clinical practice. Areas covered: The authors explore the main advancements from Aβ-targeting monoclonal antibodies (mAbs) for the treatment of AD. From a public health perspective, they address ethically relevant issues such as the benevolence and non-maleficence principles. They report on the potential biological and clinical benefits of these drugs, discussing minimal clinically important differences (MCID) and other relevant outcomes. They examine the short- and long-term effects of amyloid-related imaging abnormalities (ARIA), and explore the differences between eligibility criteria in clinical trials, appropriate use recommendations, and prescribing information content. In doing so, they contextualize the discussion on the disagreements among different regulatory authorities. Expert opinion: Although anti-β-amyloid monoclonal antibodies may be effective in selected scenarios, non-negligible knowledge gaps and implementation limits persist. Overcoming these gaps can no longer be postponed if we are to ensure the principles of Quality of Care for patients with cognitive impairment who would be eligible for this class of drugs.File | Dimensione | Formato | |
---|---|---|---|
Salemme et al. 2023.pdf
solo gestori archivio
Note: Salemme_Advances in amyloid-targeting_2023
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
982 kB
Formato
Adobe PDF
|
982 kB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.